Customer
An American multinational biopharmaceutical company and one of the world’s largest independent biotechnology companies with presence in approximately 100 countries and regions worldwide. The company focuses on four therapeutic areas, oncology, inflammation, general medicine and rare disease, delivering innovative medicines that have reached millions of people in the fight against serious illnesses.
Challenges
Fragmented Medical Affairs Operations with multiple AORs at Global and Local level leading to:
- Duplication of efforts for asset creation and review
- Ineffective resource utilization – especially TA lead’s time
- Lack of synergy between Medical teams
- No traceability between global to local assets
All of the above had been leading to redundancies, high costs, delayed time to market, and missed out deadlines
Scope: 115+ Brands across US, Canada, EU, JAPAC, LATAM, MEA. The brands catered to therapies across Oncology, Nephrology, Hematology, Bone, Cardiovascular, Neurology, Inflammatory, Biosimilars Pipeline molecules
Indegene Solution
Indegene centralized all the medical content services across brands and regions and deployed a “TA Pod”-based content delivery model
We implemented a common asset repository for ease of discovery with efficient tagging of content
Global content modules were reviewed extensively for “first time right” MLR strategy. Derivative local assets were re-adapted and reviewed by country-based specialists.
A robust demand forecasting, management and planning system helped streamline operations and optimize content creation strategy
Outcomes
Indegene’s centralized medical content services, including deployment of a "TA Pod" model ensured "first-time-right" MLR and optimized content strategy. The robust demand forecast and planning system ensure streamlined operations. The outcomes included over 40% increase in content reuse, approximately 45% reduction in costs year-on-year, and more than 30% increase in speed to market.
>40%
Increase in content reuse
~45%
Reduction in costs year-on-year
>30%
Increase in Speed to Market
Learn how a multinational biopharma company activated insights-driven decisions using unified Medical Affairs dashboard.
Learn how a global pharma improves customer experience at 50% lesser costs with revamped SRLs across 5+ therapeutic areas.